Sign In
Buy ICAD
$3.87
+0 (+0%)
At Close: Oct 16, 2025
4 Specialized AI Stocks to Buy for the Boom
01:06pm, Tuesday, 31'st Aug 2021
Companies with focused AI technologies appear to be doing better than firms with AI based on general data. Here are four AI stocks to buy.
iCAD, Inc. (ICAD) CEO Michael Klein on Q2 2021 Results - Earnings Call Transcript
11:12am, Sunday, 08'th Aug 2021
iCAD, Inc. (ICAD) CEO Michael Klein on Q2 2021 Results - Earnings Call Transcript
iCAD Q2 Earnings Lag Street Estimates As Sales Impacted By Longer Enterprise Sales Cycles
11:05am, Friday, 06'th Aug 2021
iCAD Inc (NASDAQ: ICAD) reported Q2 adjusted EPS loss of $(0.11) slightly better than $(0.12) a year ago, but missing the consensus of $(0.07). Sales increased 41% Y/Y to $7.8 million, missing the
Icad (ICAD) Reports Q2 Loss, Lags Revenue Estimates
07:46pm, Thursday, 05'th Aug 2021
Icad (ICAD) delivered earnings and revenue surprises of -37.50% and -14.19%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
iCAD to Participate in the Guggenheim MedTech Disruptors Summit
04:05pm, Monday, 02'nd Aug 2021
NASHUA, N.H., Aug. 02, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Michael
iCAD to Report Second Quarter 2021 Financial Results on Thursday, August 5
04:01pm, Thursday, 22'nd Jul 2021
NASHUA, N.H., July 22, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will
iCAD's ProFound AI for Digital Breast Tomosynthesis Version 3.0 Receives CE Mark Approval
08:00am, Monday, 14'th Jun 2021
iCAD's third generation artificial intelligence solution for 3D mammography offers considerable improvement in algorithm specificity performance and faster processing compared to previous generations
iCAD: Cancer Detection And Therapy Solutions Company Offers Stable Upside
05:35pm, Wednesday, 19'th May 2021
iCAD, Inc. is a global medical technology company developing cancer detection and therapy solutions across their two respective segments. ICAD operates across two segments: Detection and Therapy offer
Company sees positive momentum as research contributes to growing body of evidence supporting Xoft intraoperative radiotherapy (IORT) technology for brain cancer Company sees positive momentum as rese
iCAD, Inc. (ICAD) CEO Michael Klein on Q1 2021 Results - Earnings Call Transcript
12:53am, Thursday, 29'th Apr 2021
iCAD, Inc. (ICAD) CEO Michael Klein on Q1 2021 Results - Earnings Call Transcript
Icad (ICAD) Reports Q1 Loss, Tops Revenue Estimates
06:17pm, Wednesday, 28'th Apr 2021
Icad (ICAD) delivered earnings and revenue surprises of 36.36% and 6.36%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
iCAD Reports Financial Results for First Quarter Ended March 31, 2021
04:01pm, Wednesday, 28'th Apr 2021
First Quarter Revenues of $8.6 Million Represented 32% Year-Over-Year Growth Driven by 28% Growth in Detection Revenue and 41% Growth in Therapy Revenue
iCAD Announces Estimated Q1 Revenues and Upcoming CFO Transition
04:01pm, Monday, 05'th Apr 2021
Company expects preliminary estimated revenues to exceed $8.1 million
iCAD Shares On The Rise After FDA Approval For Third Version Of ProFound AI For 3D Mammography
07:42am, Tuesday, 16'th Mar 2021
The FDA has approved iCAD Inc's (NASDAQ: ICAD) ProFound AI Version 3.0 for Digital Breast Tomosynthesis (also known as “3D” mammography used to improve the ability to detect early breast cance
ICAD Stock Price Increases Over 15% Pre-Market: Why It Happened
06:07am, Tuesday, 16'th Mar 2021
The stock price of iCAD Inc (NASDAQ: ICAD) has increased by over 15% pre-market. This is why it happened.
